Answers are grounded in this paper and cite their sources.
BACKGROUND: UniFluVec is a live attenuated recombinant influenza vaccine candidate designed to enhance mucosal immunity and provide broad cross-protective responses after intranasal administration. This Phase 1 randomized, double-blind, placebo-controlled trial evaluated its safety and tolerability in healthy adults. METHODS: Sixty volunteers aged 18-49 years were randomized to receive two intranasal doses of UniFluVec (6.7 or 7.7 log10EID50) or placebo, administered 21 days apart. Safety assessments included local and systemic reactogenicity, unsolicited adverse events (AEs), serious AEs (SAEs), clinical laboratory parameters, vital signs, and evaluation of viral shedding using rapid antigen testing. RESULTS: UniFluVec was well tolerated at both dose levels. No vaccine-related SAEs or clinically significant safety signals were observed. The most frequently reported adverse events were mild local reactions – primarily nasal congestion, rhinorrhea, and sore throat – which resolved spontaneously. Systemic symptoms, including low-grade fever, headache, fatigue, and myalgia, were infrequent, transient, and predominantly mild. No vaccine-related abnormalities were detected in the hematological, biochemical, or vital-sign parameters. No influenza A virus was detected in any volunteer at any study visit according to the express test results. The reactogenicity did not increase after the second dose. CONCLUSION: UniFluVec demonstrated a favorable safety and tolerability profile in healthy adults, with no clinically meaningful adverse events reported. These findings support the further clinical development of UniFluVec as a universal influenza vaccine candidate. Clinical Trial Registration number: NCT04650971 (2020-12-03).
No takes yet. Share an insight, caveat, or question.
Stukova et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: